Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Neurointerventionalists have broadly adopted dual antiplatelet treatment (DAPT) strategies from cardiologists owing to the lack of high-level evidence in the neuroendovascular field.1 2 A pooled analysis on flow diversion treatment using DAPT estimated an overall risk of thromboembolic and hemorrhagic complications of 7% (95% CI 6% to 9%) and 5% (95% CI 4% to 6%), respectively.3 Surveys on DAPT strategies across major academic neurovascular centers in the USA demonstrated significant variation in the choice of antiplatelet regimen, the duration of administration of antiplatelet drugs, employment of platelet function testing, and the choice and duration of alternate antiplatelet therapy for hypo-responders and non-responders to clopidogrel.4 5 Recently, a randomized trial underpinned the value of antiplatelet therapy guided by platelet function monitoring to reduce thromboembolic complications in patients undergoing intracranial stent placement for cerebral aneurysms.6
We read the article ‘Effect of body weight on VerifyNow Aspirin platelet function test: a retrospective review’ by Sandler et al with great interest.7 Briefly, the authors analyzed VerifyNow assay results in 142 patients who had undergone neuroendovascular stent placement. Most patients were Caucasian (80.3%), non-obese (body mass index <30 in 64.8%), and received an aspirin dose of 300–325 mg (88.7%) with clopidogrel (94.4%) as the concomitant P2Y12 inhibitor. According to the authors’ institutional protocol, dual antiplatelet therapy was initiated 5–7 days before the intervention in elective cases. A total of 83.8% of patients achieved an initial therapeutic VerifyNow Aspirin assay result (aspirin reaction units (ARU) <550) and 86.2% (119/138) an initial therapeutic VerifyNow P2Y12 assay (P2Y12 reaction units (PRU) <215). Thus, the authors concluded that body weight did not influence the likelihood of obtaining a therapeutic VerifyNow Aspirin result and, perhaps more broadly, the clinical usefulness of …
Contributors PH: conception and design of the work, data collection and interpretation, drafting the article, final approval of the version to be published. CJG and CMS: data interpretation and critically revising the article, final approval of the version to be published.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests CMS received research funding from Penumbra and has ownership in NTI. CJG received research funding from Medtronic, Penumbra, and consulting honoraria from Stryker, MicroVention. None of the authors have conflicts of interest related to the work.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.